Bristol-Myers Squibb ranked number three in Corporate Responsibility magazine's 2013 list of the 100 Best Corporate Citizens. The company ranked first in 2012 and 2009.

In April, Bristol-Myers Squibb was chosen as one of the 2013 Top 50 Companies for Diversity by Diversity Inc. The ranking is based on a company’s answers to a detailed survey divided into four equally weighted areas: CEO Commitment, Human Capital, Corporate and Organizational Communications and Supplier Diversity. This year, 893 companies participated in the survey.

For the eighth year in a row, Bristol-Myers Squibb received the top rating of 100 percent in the Corporate Equality Index. The report, released annually by the Human Rights Campaign Foundation -- the nation’s largest lesbian, gay, bisexual and transgender civil rights organization -- provides an in-depth analysis and rating of large U.S. employers and their policies and practices. This year’s index rated 688 businesses.

In February 2013, the National Association for Female Executives selected Bristol-Myers Squibb as one of the Top 50 Company for Executive Women, for the 11th consecutive year. Companies on this year’s list of 50 companies must have at least two women on the board of directors, a significant number of women in senior ranks and programs and policies that support women’s advancement.

In September 2012, Bristol-Myers Squibb was recognized as one of the 2012 Working Mother 100 Best Companies – marking the 15th consecutive year that our company has made the list. In recognition of the achievement, Bristol-Myers Squibb will be inducted into the Working Mother Hall of Fame this year.

In July 2012, Ethisphere Institute, a leading international think-tank dedicated to the research and promotion of best practices in corporate ethics and compliance, awarded Bristol-Myers Squibb the Compliance Leader Verification Award. The award recognizes companies with best-in-industry ethics and compliance programs -- those organizations that have made the decision to proactively invest resources in compliance, sending a clear signal to key stakeholders that compliance and ethics are an absolute organizational priority.

DiversityBusiness.com has named Bristol-Myers Squibb a Top 50 Organization for Multicultural Business Opportunities for 2012. The Div50, as it is known, has become the most recognized ranking of companies that differentiate themselves in the marketplace through their relationships with diverse businesses.

In 2011, Bristol-Myers Squibb received a Prime Company rating for the fourth time in a row from oekom research, a leading European sustainability rating firm. Using social and environmental criteria, Prime Status is awarded to companies that are among the leaders in their industry.

Bristol-Myers Squibb was recognized as 78th among 500 of America’s largest corporations in Newsweek’s 2012 Green Rankings.

In January 2011, Bristol-Myers Squibb was recognized by R&D Directions magazine as having the “Most Innovative Pipeline” within the pharmaceutical industry.

According to a report released by the Roberts Environmental Center at Claremont McKenna College, Bristol-Myers Squibb earned the highest score in the pharmaceutical sector for sustainability reporting. The report compiled Pacific Sustainability Index scores evaluating the environmental and social reporting of the 26 largest pharmaceutical companies worldwide.

Bristol-Myers Squibb was recognized as the 2009 Trailblazer Company of the Year by PM360 magazine. Among the criteria for selection were civic involvement, patient access, environmental consciousness, employee development and innovation.

Our corporate website was recognized with the Best in Class award for a pharmaceutical company in 2009 by the Interactive Media Awards.

Bristol-Myers Squibb was recognized in the 2009 Dow Jones Sustainability North America Index of leading sustainability-driven companies.

Bristol-Myers Squibb's Investor Relations department was rated the best in the pharmaceutical business by investors polled by Institutional Investor magazine, a leading international business-to-business publisher focused primarily on international finance.

Bristol-Myers Squibb awarded the Allicense 2009 Breakthrough Alliance Award for collaboration with Exelixis. This is the second year in a row that the company has been presented with this prestigious recognition, which honors the world's best and most innovative partnerships between biotechnology and pharmaceutical companies.

FORTUNE China named Bristol-Myers Squibb China a Top Ten Green Company for 2009 in recognition of Bristol-Myers Squibb's hepatitis awareness, prevention and care efforts in Asia. Since 2002, Bristol-Myers Squibb China has partnered with the Bristol-Myers Squibb Foundation and local non-profit organizations on 11 hepatitis prevention and control projects that have directly benefited seven million people.

Barron's 2009 Most Respected Companies Survey includes Bristol-Myers Squibb as the world's 40th most respected company. The survey reflects opinions of money managers for the 100 largest public companies in the world based on stock market capitalization. A variety of attributes contribute to the overall score, including strong management, sound business strategy, ethical practices and financial performance.

Calvert, a leader in socially responsible investing, has created the Calvert Social Index®, a broad-based, rigorously constructed benchmark for measuring the performance of socially responsible companies. Calvert's Social Research Department analyzes the top 1,000 largest U.S. companies annually. Bristol-Myers Squibb has been on its Social Index of companies since 2003.

The Asian American Legal Defense and Education Fund honored Sandra Leung, senior vice president, general counsel and corporate secretary, as a recipient of its 2009 Justice in Action Award. The award, which recognizes exceptional individuals for their outstanding achievements and contributions in advancing justice and equality, was presented in March in New York.

The Division of Medicinal Chemistry of the American Chemical Society will present John E. Macor, executive director, Neuroscience Discovery Chemistry, Research and Development, with the 2009 Robert M. Scarborough Memorial Award. This prestigious achievement recognizes scientists under the age of 50 who have documented success in the discovery of pharmaceutical compounds and who have made significant research contributions in medicinal chemistry. Macor was cited for the discovery of an anti-migraine medicine as well as a number of other clinical discoveries. The society will bestow the award at its annual meeting later this year.